Medpace Holdings, Inc. (NASDAQ:MEDP) Receives Average Rating of "Hold" from Brokerages

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) have earned a consensus recommendation of "Hold" from the fourteen research firms that are presently covering the company, MarketBeat.com reports. Eleven investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $344.82.

A number of brokerages recently issued reports on MEDP. William Blair restated a "market perform" rating on shares of Medpace in a research note on Tuesday, April 22nd. Leerink Partners began coverage on shares of Medpace in a report on Monday, March 24th. They set a "market perform" rating and a $330.00 price target for the company. Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a research report on Monday, March 24th. Robert W. Baird reduced their price objective on Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a research report on Wednesday, April 23rd. Finally, Barclays initiated coverage on Medpace in a report on Tuesday, June 24th. They set an "equal weight" rating and a $300.00 price target on the stock.

Insider Transactions at Medpace

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of Medpace stock in a transaction dated Thursday, April 24th. The stock was sold at an average price of $301.82, for a total value of $516,715.84. Following the transaction, the director directly owned 2,998 shares in the company, valued at approximately $904,856.36. The trade was a 36.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 20.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Medpace

Several large investors have recently bought and sold shares of the stock. Geneos Wealth Management Inc. raised its position in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock valued at $29,000 after buying an additional 37 shares during the last quarter. Brooklyn Investment Group increased its stake in Medpace by 244.8% during the first quarter. Brooklyn Investment Group now owns 100 shares of the company's stock valued at $30,000 after acquiring an additional 71 shares during the period. SBI Securities Co. Ltd. acquired a new position in Medpace in the 4th quarter valued at approximately $31,000. Whittier Trust Co. grew its holdings in shares of Medpace by 47.3% during the 1st quarter. Whittier Trust Co. now owns 109 shares of the company's stock worth $33,000 after purchasing an additional 35 shares in the last quarter. Finally, Jones Financial Companies Lllp raised its stake in shares of Medpace by 2,750.0% in the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock valued at $38,000 after purchasing an additional 110 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Stock Performance

Shares of NASDAQ:MEDP traded down $2.60 during midday trading on Friday, hitting $318.90. 372,191 shares of the company's stock traded hands, compared to its average volume of 374,902. The firm's fifty day moving average price is $303.74 and its two-hundred day moving average price is $319.15. The company has a market cap of $9.17 billion, a PE ratio of 24.34, a P/E/G ratio of 5.80 and a beta of 1.47. Medpace has a twelve month low of $250.05 and a twelve month high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Monday, April 21st. The company reported $3.67 earnings per share for the quarter, beating the consensus estimate of $3.06 by $0.61. The business had revenue of $558.57 million during the quarter, compared to the consensus estimate of $528.38 million. Medpace had a net margin of 19.31% and a return on equity of 54.36%. During the same period in the prior year, the firm earned $3.20 earnings per share. As a group, equities research analysts anticipate that Medpace will post 12.29 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.